First, our design focused on a short-term, high-dose oral gavage model to characterize sub-acute hazard profiles
A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
doi: 10.1186/s12883-019-1433-0 23 HoldenSMaksoudREaton-FitchNCabanasHStainesDMarshall-GradisnikS
Association Between GLP-1 Receptor Agonist Use and Worsening Mental Illness in People with Depression and Anxiety in Sweden: a National Cohort Study